Health Care • Biotechnology: Pharmaceutical Preparations
$818.77 ▲ +5.50
(+0.68%)
MKT CAP: $84.30B • VOL: 789.3K
52W L $592 52W H $935
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$688
MEDIAN
$917
MEAN
$933
HIGH
$1,114
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE REGN TAPE
REGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $990.71 | $941.59 | 2025-02-14 | $745.08 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1,031.65 | $966.15 | 2025-02-06 | $769.64 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $933.40 | $900.65 | 2025-01-29 | $786.02 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $835.15 | — | 2025-01-17 | $802.39 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $720.52 | $777.83 | 2025-01-09 | $728.71 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $974.34 | $851.52 | 2024-12-18 | $712.33 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $794.21 | $826.96 | 2024-12-04 | $761.46 | -4.3% | 48% | C |